Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does RITUXIMAB Cause Polyomavirus-associated nephropathy? 236 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 236 reports of Polyomavirus-associated nephropathy have been filed in association with RITUXIMAB (Rituxan). This represents 0.1% of all adverse event reports for RITUXIMAB.

236
Reports of Polyomavirus-associated nephropathy with RITUXIMAB
0.1%
of all RITUXIMAB reports
41
Deaths
90
Hospitalizations

How Dangerous Is Polyomavirus-associated nephropathy From RITUXIMAB?

Of the 236 reports, 41 (17.4%) resulted in death, 90 (38.1%) required hospitalization, and 22 (9.3%) were considered life-threatening.

Is Polyomavirus-associated nephropathy Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for RITUXIMAB. However, 236 reports have been filed with the FAERS database.

What Other Side Effects Does RITUXIMAB Cause?

Off label use (39,751) Drug ineffective (32,186) Rheumatoid arthritis (19,850) Pain (16,675) Fatigue (15,602) Arthralgia (12,529) Rash (12,102) Drug intolerance (11,876) Infusion related reaction (11,871) Joint swelling (11,170)

What Other Drugs Cause Polyomavirus-associated nephropathy?

TACROLIMUS (1,477) MYCOPHENOLATE MOFETIL (1,112) PREDNISONE (666) METHYLPREDNISOLONE (416) PREDNISOLONE (402) BASILIXIMAB (298) EVEROLIMUS (247) CYCLOSPORINE (246) MYCOPHENOLIC ACID (238) SIROLIMUS (161)

Which RITUXIMAB Alternatives Have Lower Polyomavirus-associated nephropathy Risk?

RITUXIMAB vs RITUXIMAB-ABBS RITUXIMAB vs RITUXIMAB-ARRX RITUXIMAB vs RITUXIMAB-PVVR RITUXIMAB vs RIVAROXABAN RITUXIMAB vs RIVASTIGMINE

Related Pages

RITUXIMAB Full Profile All Polyomavirus-associated nephropathy Reports All Drugs Causing Polyomavirus-associated nephropathy RITUXIMAB Demographics